Riskpilot← Back to searchSign inGet full accessVitaSpe Oy
OYActiveY-tunnus 3109813-5Jaakonkatu 3Medical specialists activities · NACE 8622Est. 20202 employees
Revenue 2024
EUR 546K
+8% vs 2023
EBITDA margin
17.7%
+383% vs 2023
Equity ratio
97.2%
Financial strength
Net profit 2024
EUR 58K
2 employees
| Revenue | EUR 546K | +8% |
| EBITDA | EUR 96K | +383% |
| Net profit | EUR 58K | — |
| Total assets | EUR 455K | -4% |
| Equity | EUR 442K | +6% |
| Employees | 2 | — |
Legal name
VitaSpe Oy
Y-tunnus number
3109813-5
Legal form
Osakeyhtiö
NACE code
8622 · Medical specialists activities
Founded
8. tammikuuta 2020
Share capital
EUR 0
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Toimitusjohtaja yksin
Company purpose
Lääkäri-, erikoislääkäri ja muiden terveyspalvelujen tuottaminen potilaille. Terveydenhuollon konsultointi ja koulutus sekä asiantuntijapalvelut, konsultointi-, tutkimus- ja koulutuspalvelut. Yritys voi omistaa, hallita ja vuokrata kiinteistöjä sekä asuin- ja liikehuoneistoja. Yrityksen toiminta voi olla kansainvälistä. Yritys voi harjoittaa arvopaperikauppaa.
Address
Jaakonkatu 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 365 | 579 | 640 | 505 | 546 |
| Staff expenses | −41 | −260 | −125 | −243 | −225 |
| EBITDA | 213 | 198 | 308 | 20 | 96 |
| Depreciation & amort. | −9 | −36 | −37 | −34 | −27 |
| EBIT | 204 | 162 | 272 | 0 | 69 |
| Net financials | — | −1 | −2 | 0 | 0 |
| Profit before tax | 204 | 161 | 270 | 0 | 68 |
| Tax | 41 | 33 | 55 | −0 | −0 |
| Net profit | 162 | 128 | 215 | 0 | 58 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 207 | 418 | 554 | 473 | 455 |
| Equity | 162 | 277 | 472 | 418 | 442 |
| Long-term debt | — | 65 | 35 | 5 | 0 |
| Short-term debt | 44 | 76 | 46 | 49 | 13 |
| Total debt | 44 | 141 | 82 | 55 | 13 |
EBITDA margin
17.7%
This company
15.8%
Market median
+12% vs market
20202024
Equity ratio
97.2%
This company
38.2%
Market median
+154% vs market
20202024
Return on equity
13.0%
This company
18.4%
Market median
+29% vs market
20202024
Net profit margin
10.6%
This company
8.1%
Market median
+31% vs market
20202024
Asset turnover
1.20×
This company
1.12×
Market median
+7% vs market
20202024
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
SD Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2020 |
AD Chief Executive Officer | Chief Executive Officer | 2020 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of VitaSpe Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Shorsh Dero | Deputy Chief Executive Officer | 0 companies |
| Avesta Dero | Chief Executive Officer | 0 companies |